Trial Profile

Efficacy of ALXN1840 on human hepatic copper uptake quantified with 64CuCl2 PET/CT-scan. Effekten af ALXN1840 på kobberoptag i leveren målt ved 64CuCl2 PET/CT

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tiomolibdate choline (Primary) ; Penicillamine; Trientine
Indications Hepatolenticular degeneration
Focus Pharmacodynamics
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

09 Dec 2023 Results from EudraCT2020-005832-31 and EudraCT 2021-000102-25 , investigating the effects of TTM on copper absorption and biliary excretion published in the Journal of Hepatology
24 Jun 2023 Results presented at the European Association for the Study of the Liver Congress 2023
07 Jul 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com